21 CFR 522.2473

§ 522.2473 Tiludronate.

United States · 21 CFR — Food and Drugs · Status: effective

Cite this

Citation: 21 CFR 522.2473, § 522.2473 Tiludronate, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87551
Permanent ID: ys:prov:87551@1
SHA-256: d0880c78728d8af807b2c3f780cc993e74c6272648f739f6c0b667ec72df04fd

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) Specifications. Each vial of powder contains 500 milligrams (mg) tiludronate disodium. Each milliliter of constituted solution contains 20 mg tiludronate disodium. (b) Sponsor. See No. 061133 in § 510.600(c) of this chapter. (c) Conditions of use in horses—(1) Amount. Administer a single dose of 1 mg per kilogram (0.45 mg/pound) of body weight by intravenous infusion. (2) Indication for use. For the control of clinical signs associated with navicular syndrome. (3) Limitations. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.